OP-1250 (Palazestrant)

palazestrant · Olema Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OP-1250 (Palazestrant), covering 2025-10-22 to 2025-10-22. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer [Phase 1]

See pricing